# A Study of the Efficacy and Safety of Pregabalin as Add-On Therapy for Partial Onset Seizures in Children Ages 4-16 Years

> **NCT01389596** · PHASE3 · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 295 (actual)

## Conditions studied

- Epilepsy, Partial Seizures

## Interventions

- **DRUG:** Pregabalin add-on therapy
- **DRUG:** Pregabalin add-on therapy
- **DRUG:** Pregabalin add-on therapy

## Key facts

- **NCT ID:** NCT01389596
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09-27
- **Primary completion:** 2016-08-10
- **Final completion:** 2016-08-10
- **Target enrollment:** 295 (ACTUAL)
- **Last updated:** 2021-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01389596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01389596, "A Study of the Efficacy and Safety of Pregabalin as Add-On Therapy for Partial Onset Seizures in Children Ages 4-16 Years". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01389596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*